CytoTrack
Lyngby
About CytoTrack
CytoTrack is a medical company that offers a technology platform for the detection of Circulating Tumor Cells in blood. The key feature is the detection of CTCs without being dependent on EpCAM enrichment or filtration based on size. The scanner has an ultra-high scanning capacity of 100 million cells in just a minute. Single intact cells can be isolated with the CytoPicker feature, for downstream applications such as Single Cell PCR and FISH. The technology was invented as a part of a research development project at The National Hospital of Denmark. The project was headed by Professor John Philip. The application was to identify FCMB (Foetal Cells in Maternal Blood). The project discovered that conventional instruments such as flow cytometry and common fluorescent scanners were not good enough for this type of application could not detect the extremely rare fetal cells and could not offer features for molecular characterization. The CytoTrack technology was invented and developed specifically for the challenges of rare cell detection by Christian Caspersen. Other applications such as the detection of CTCs were soon adopted.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $59.2K
- Last round: Grant (Jan 2015)
- Website: cytotrack.com
- Phone: +45 70 27 52 00
Industries & Categories
Biotechnology, Health Diagnostics, Hospital, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/cytotrack-2139806 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.